Investors
Investors
Corporate Profile
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com.
Receive Email Alerts
Sign up to receive email alerts whenever Jaguar Health, Inc. posts new information to the site. Just enter your email address and click Submit.
Receive Text Alerts
To sign up for Jaguar Health’s news alert text service, click here. Whenever the company issues a new press release, investors participating in Jaguar Health’s news alert text service will receive a text message with a link to the release. No mobile information will be shared with third parties/affiliates for marketing/promotional purposes at any time.
